...Cell therapy developer Adicet will merge with resTORbio to form a public company that will trade...
...for a contingent value right payable to resTORbio’s shareholders under certain conditions. In November 2019, resTORbio...
...equity, and resTORbio’s will hold the balance. The combined company's president and CEO will be resTORbio...

...company is moving forward with the mTORC1 inhibitor in Parkinson’s disease and other age-related indications. resTORbio Inc....
...IIb trial in July 2018, non-significantly reducing CSRIs by 15.3% vs. placebo (one-sided p=0.27). But resTORbio...
...“resTORbio Forging Ahead With Anti-infective After Phase IIb Readout” ). On a conference call Friday, resTORbio...

...NYSE-M:OGEN) (A) 3/22/19 $12.5 NA $22.6 NA Dermira Inc. (NASDAQ:DERM) 3/21/19 $149.5 $710.3 $513.1 -28% resTORbio Inc....

...could treat the disease. By contrast, Dionne said other companies with autophagy-related programs, including resTORbio Inc....
...of preparation and filing but did not disclose what the IP covers. A spokesperson for resTORbio...
...Therapeutics Inc., Cambridge, Mass. Michael J. Fox Foundation For Parkinson's Research (MJFF), New York, N.Y. resTORbio Inc....

...NASDAQ:DTIL) hired Christopher Heery as CMO. He was CMO of Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY). resTORbio Inc....
...Corp. Amunix Pharmaceuticals Inc. Beam Therapeutics CytoDyn Inc. DBV Technologies S.A. Glympse Bio Inc. Life Biosciences LLC Novigenix S.A. Precision BioSciences Inc. Rafael Pharmaceuticals Inc. resTORbio Inc....

...million in an upsized offering that followed closely after its eczema readout this week, while resTORbio...
...Fitzgerald, Guggenheim Securities, Needham and H.C. Wainwright. Dermira was off $0.49 to $13.64 on Wednesday. resTORbio Inc....
...pricing 7.2 million shares at $6.95, a 23% discount to Monday's closing price of $9.05. resTORbio...

...with seven pharmas. PureTech holds a majority stake in eight of its 10 private companies. resTORbio Inc....
...and Merck KGaA (Xetra:MRK) are investors rather than collaborators in Akili Interactive Labs Inc. (B) resTORbio...
...58.4% Phase II None Sonde Health Voice-based biomarkers Neurology 93.1% Phase I None IMMUNE SYSTEM resTORbio Inc....

...chief commercial officer. He was SVP of commercial at Heron Therapeutics Inc. (NASDAQ:HRTX). Aging company resTORbio Inc....
...Therapeutics Inc. BioTime Inc. Deciphera Pharmaceuticals Inc. Flatiron Health Inc. Gamida Cell Ltd. Genentech Inc. Heron Therapeutics Inc. Immune-Onc Therapeutics Inc. Melinta Therapeutics Inc. resTORbio Inc. Roche Shire...

...Fund, but did not specify his new role. Steinberg has co-founded several biotechs, including PureTech, resTORbio Inc....

...Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent...
...trial's Parts 1 and 2 in which one dose did significantly improve the primary endpoint, resTORbio...
...ages 65 and older with asthma, and patients ages 65 and older who are non-smokers. resTORbio...